ライフサイエンスコーパス: PPI

1 PPI dose escalation and continued chronic therapy in tho

2 PPI hubs reveal new regulatory mechanisms for cancer gen

3 PPI modulation requires novel approaches and the integra

4 PPI treatment significantly reduces the need for phlebot

5 PPI usage up to 90 days before the index date remained s

6 PPI use also associated with development of end-stage re

7 PPI use was defined as more than 30 cumulative defined d

8 PPI use with LDV/SOF +/- RBV did not affect SVR (89.7% [

9 PPI+ subjects were older and more likely to have hyperte

10 PPI-binding domains rapidly (< 1 s) accumulate at damage

11 PPIs have the potential to induce life-threatening DHR.

12 PPIs may have unwanted side effects in vulnerable popula

13 re predicted to have up to 18,000 and 31,000 PPIs, respectively.

14 ate binary (1 x 1) and ternary (1 x 2) Bcl-2 PPI analyses by imaging fluorescent protein translation

15 feasibility to identify a PPI inhibitor, 26 PPIs in DDR pathways (BER, MMR, NER, NHEJ, HR, TLS, and

16 oaches explored for the modulation of 14-3-3 PPIs and review the examples resulting from these effort

17 e recruited 77 HIV-infected participants (37 PPI+ and 40 PPI-) and 20 HIV-uninfected volunteers.

18 Next, we perform a 1 x 4 PPI network analysis by direct measurement of four uniqu

19 77 HIV-infected participants (37 PPI+ and 40 PPI-) and 20 HIV-uninfected volunteers.

20 r respective species data, we found only 429 PPIs ( 1% of the available data) conserved in two or mor

21 ronger for higher daily doses (>1.5 vs <0.75 PPI pills/d; P value interaction = .004) and decreased a

22 ed transcription factor (TF) requires both a PPI to deliver a protease proximal to its cleavage pepti

23 Patients with a proven indication for a PPI should continue to receive it in the lowest effectiv

24 le and biochemical feasibility to identify a PPI inhibitor, 26 PPIs in DDR pathways (BER, MMR, NER, N

25 g development commonly involves inhibiting a PPI, in this study, we show that stabilizing PPI may als

26 be solved for any linear peptoid, revealed a PPI helix of great regularity despite the presence of on

27 ans and patients should not avoid starting a PPI because of concerns related to MI risk.

28 ophagitis or peptic stricture) should take a PPI for short-term healing, maintenance of healing, and

29 r-related bleeding from NSAIDs should take a PPI if they continue to take NSAIDs.

30 proof of a supramolecular ligand targeting a PPI interface and stabilizing the binding of an intrinsi

31 led to much of the current controversy about PPI safety.

32 e high background and lose information about PPI dynamics.

33 While acoustic PPI remained intact and ABR thresholds recovered, the AB

34 sitivity, SPARK has the potential to advance PPI analysis and discovery.

35 s amplify fluorescence intensities and allow PPIs to be interrogated using standard epifluorescence m

36 -100 mg/kg, IP) dose-dependently ameliorated PPI deficits, hyperactivity, and risk-taking behaviors,

37 Among PPI users, the associations were stronger for higher dai

38 In multivariable analysis, PPI use was independently associated with ESBL-E rectal

39 innest pachymetry, ARTmax, BDE, D index, and PPI max were 0.82, 0.61, 0.88, 0.67, and 0.64, respectiv

40 lular localization, orthologous proteins and PPI networks, we propose a novel essential protein predi

41 ociation between risk of incident stroke and PPI use among participants.

42 en though this is a challenging endeavor and PPIs have long been regarded as "undruggable" targets, t

43 and identification of >260 cancer-associated PPIs not in other large-scale interactomes.

44 he commonly prescribed and cheaply available PPI lansoprazole was associated with reduced incidence o

45 not observe a convincing association between PPI use and cognitive function.

46 d not find a significant association between PPI use and ischemic stroke, after accounting for indica

47 We investigated the association between PPI use and ischemic stroke.

48 analyses to estimate the association between PPI use and the occurrence of HE.

49 We therefore examined associations between PPI use and performance in tests of cognitive function.

50 te to establish causal relationships between PPI therapy and many of the proposed associations.

51 We investigated the association between PPIs and specific fracture sites using an aggregated kno

52 y significant associations (signals) between PPIs and fractures.

53 Both PPI scoring and the bulk of strain construction can be p

54 hypersensitivity reactions (DHR) induced by PPI, such as Stevens-Johnson syndrome (SJS), toxic epide

55 involving ATM and DNA-PKcs are unaffected by PPI sequestration.

56 We analyzed the causative PPI, clinical manifestations, organ involvement, treatme

57 n 30 cumulative defined daily doses (cDDDs); PPI nonuse was defined as 30 cDDDs or fewer.

58 re of an Ns1tbe pentamer revealed an all-cis PPI helix, and the CD curves of the Ns1tbe oligomers als

59 and uncover inhibitor-dependent competitive PPIs.

60 Initiation of PPI therapy and cumulative PPI exposure is associate with increased risk of CKD pro

61 me-dependent risk associated with cumulative PPI exposure.

62 noSPD for a range of nuclear and cytoplasmic PPIs implicated in human deafness, in addition to dissec

63 PPiSeq detects PPIs at a rate that is on par with current assays and, i

64 could tolerate other structurally different PPI without cross-hypersensitivity reactions, whereas th

65 SPARK was used to detect 12 different PPIs in mammalian cells, with 5 min temporal resolution

66 hich models the conformation of a disordered PPI by considering the biophysical binding mechanism of

67 On a dataset of 22 disordered PPIs with IDPs up to 69 amino acids, successful predicti

68 ng of the molecular mechanisms of disordered PPIs, it is crucial to obtain the tertiary structure of

69 into the molecular mechanisms of disordered PPIs.

70 ethods have difficulty in solving disordered PPIs and existing protein-protein and protein-peptide do

71 Based on data mining from AERS-DM, PPI use appears to be associated with an increased risk

72 vestigate whether Galphai-GIV is a druggable PPI.

73 ol for large-scale investigations of dynamic PPIs.

74 Each PPI-mediated RNAPN-RNAPC assembly transcribes from a sep

75 nerating a unique RNA output signal for each PPI.

76 lly reevaluated so that the lowest effective PPI dose can be prescribed to manage the condition.

77 The magnitude of amphetamine-enhanced PPI was greater in patients than in HS (p<0.032), and wa

78 In the year prior to enrollment, PPI+ group lost more CD4 cells than PPI- (-18 vs. 54 cel

79 After placebo, patients exhibited PPI deficits with 60 ms prepulse intervals; these defici

80 Although experimental PPI data have increased significantly over recent years,

81 In fact, PPI can reveal how inter-regional amygdala communication

82 Finally, PPI deficits were exacerbated by allopregnanolone (10 mg

83 OncoPPi is a focused PPI resource that links cancer genes into a signalling n

84 we report the generation of a cancer-focused PPI network, termed OncoPPi, and identification of >260

85 eed and attention (mean score difference for PPI use of 9-14 years vs never users, -0.06; 95% confide

86 er we adjusted for potential indications for PPI use, including history of peptic ulcer disease, gast

87 stroke, after accounting for indications for PPI use.

88 General requirements for PPI strategies, such as selecting the target PPI site on

89 ression of transgenes are powerful tools for PPI discovery, screens, and analysis of cell populations

90 patients who started a new prescription for PPIs vs H2RAs.

91 This work establishes the Galphai-GIV PPI as a druggable target and sets the conceptual and te

92 ction of >1,000 compounds on the Galphai-GIV PPI by in silico ligand screening and separately by a ch

93 Furthermore, some patients may have had PPI therapy discontinued abruptly or inappropriately due

94 reflux symptoms, dysphagia, general health, PPI use, and need for surgical reintervention at 17 year

95 for the rapid discovery of new alpha-helical PPI modulators.

96 rategy that exploits selective alpha-helical PPIs, transferring these characteristics to small molecu

97 Hence, PPI networks are already well investigated by current al

98 e development of all-cis polyproline type I (PPI) helices, as tools for modulating biological functio

99 C) to assign weights to interaction edges in PPI networks so that protein complexes can be identified

100 omeprazole was the most commonly involved in PPI-related DHR (51%).

101 proposed approach can tolerate edge loss in PPI networks and even discover sparse protein complexes

102 risk of acute myocardial infarction (MI) in PPI users vs non-users.

103 investigated the T-cell reactivity to PPI in PPI-related DHR patients.

104 lly relevant soft clusterings of proteins in PPI networks, which may be used for refining the transfe

105 ance and timing of PPI doses), or increasing PPI dosage to twice daily in select circumstances, can r

106 eal thickness, pachymetry progression index (PPI), Ambrosio relational thickness (ART), posterior ele

107 tatus was assessed with prepulse inhibition (PPI) and auditory brainstem responses (ABRs).

108 Prepulse inhibition (PPI) of startle is being explored both as an indicator o

109 ve a profound defect in prepulse inhibition (PPI), a measure of sensorimotor gating commonly deficien

110 tudies have found the proton pump inhibitor (PPI) lansoprazole to be highly active against Mycobacter

111 age, race, cirrhosis, proton pump inhibitor (PPI) prescription, prior HCV treatment, body mass index,

112 h an empiric trial of proton pump inhibitor (PPI) therapy and complementary lifestyle measures, for p

113 ation of symptoms and proton pump inhibitor (PPI) therapy, GERD-Health Related Quality of Life scores

114 associations between proton pump inhibitor (PPI) use and dementia.

115 99, 177 patients with proton pump inhibitor (PPI)-refractory GERD were randomized to CNF or LNF.

116 BACKGROUND & AIMS: Proton pump inhibitors (PPI) are among the top 10 most prescribed medications wo

117 BACKGROUND & AIMS: Proton pump inhibitors (PPI) have been associated with acute kidney injury and r

118 BACKGROUND & AIMS: Proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2RAs) suppr

119 BACKGROUND & AIMS: Proton pump inhibitors (PPIs) are commonly used medications.

120 Proton pump inhibitors (PPIs) are widely used to treat gastric acid-related diso

121 Proton pump inhibitors (PPIs) have been known to induce type I hypersensitivity

122 sues associated with proton pump inhibitors (PPIs) have recently attracted widespread media and lay a

123 studies suggest that proton pump inhibitors (PPIs) may increase the risk for listeriosis.

124 Proton pump inhibitors (PPIs) predispose to bacterial overgrowth in the gut.

125 hronic liver disease.Proton pump inhibitors (PPIs) reduce gastric acid secretion and modulate gut mic

126 udies have suggested proton pump inhibitors (PPIs) reduce the need for phlebotomy in this population.

127 h co-prescription of proton-pump inhibitors (PPIs) reduces upper gastrointestinal bleeds by 70-90%, u

128 5% of patients using proton pump inhibitors (PPIs) were rectal carriers of extended-spectrum beta-lac

129 ith long-term use of proton pump inhibitors (PPIs), focusing on long-term use of PPIs for three commo

130 Proton pump inhibitors (PPIs), frequently prescribed to patients with cirrhosis,

131 Psycho-physiological interaction (PPI) analysis revealed that dot periodicity modulated fu

132 Comprehensive protein-protein interaction (PPI) analysis of viral proteins can eventually disclose

133 nhibitor of the protein-protein interaction (PPI) between the transcription factor Nrf2 and its negat

134 Targeting protein-protein interaction (PPI) is rapidly becoming an attractive alternative for d

135 form a coherent protein-protein interaction (PPI) network containing known and candidate meiotic prot

136 availability of protein-protein interaction (PPI) network data, several network alignment methods hav

137 , we reported a protein-protein interaction (PPI) network of cancer-associated genes, termed OncoPPi,

138 l pathways or a protein-protein interaction (PPI) network, we can find better biomarkers that lead to

139 f genes given a protein-protein interaction (PPI) network, we simulated microarray gene expression da

140 s from a single protein-protein interaction (PPI) network.

141 Traditional Protein-Protein Interaction (PPI) networks, which use a node and edge representation,

142 Psychophysiological interaction (PPI) analyses showed that coupling between the hippocamp

143 amygdala's psychophysiological interaction (PPI).

144 52,000 unique protein-protein interactions (PPIs) across 349 different bacterial species and strains

145 utic strategy, protein-protein interactions (PPIs) are considered poorly "druggable" targets requirin

146 Protein-protein interactions (PPIs) are crucial in many biological processes.

147 Protein-protein interactions (PPIs) can offer compelling evidence for protein function

148 lex network of protein-protein interactions (PPIs) has now been widely recognized as an attractive me

149 ltidimensional protein-protein interactions (PPIs) inside live mammalian cells using split RNA polyme

150 vert transient protein-protein interactions (PPIs) into stable expression of transgenes are powerful

151 lly catalogued protein-protein interactions (PPIs) of a cell in a single environment.

152 volves complex protein-protein interactions (PPIs) of PA, PB1, and PB2 subunits.

153 by focusing on protein-protein interactions (PPIs) of the key DDR components.

154 Protein-protein interactions (PPIs) of these subunits play pivotal roles in assembling

155 Protein-protein interactions (PPIs) regulate assembly of macromolecular complexes, yet

156 age Giles-host protein-protein interactions (PPIs) using yeast two-hybrid screening (Y2H).

157 re involved in protein-protein interactions (PPIs) very often display a high degree of intrinsic diso

158 ties to reveal protein-protein interactions (PPIs) with functional and therapeutic significance.

159 Disordered protein-protein interactions (PPIs), those involving a folded protein and an intrinsic

160 Here we comprehensively describe intraviral PPIs among tectivirus Bam35 proteins determined using mu

161 eveloped an innovative method to investigate PPIs of multisubunit complexes effectively and to identi

162 nce monitoring before committing to lifelong PPIs to help distinguish GERD from a functional syndrome

163 Phosphoinositide lipids (PPIs) are enriched in the nucleus and are accumulated at

164 Phosphorylated phosphoinositide lipids (PPIs) are low-abundance signaling molecules that control

165 (BDE), pachymetric progression index maximum(PPI max), and multimetric D were significantly higher co

166 Moreover, PPI is found to be more resistant to oxidative degradati

167 reased significantly over recent years, most PPI networks still have many false positive interactions

168 eriaceae (ESBL-E), compared with 2.9% of non-PPI users.

169 Amphetamine acutely 'normalized' PPI in antipsychotic-medicated schizophrenia patients; n

170 eceiving long-term PPIs (PPI+ group) or not (PPI- group), were enrolled.

171 highlights the unique features of Keap1-Nrf2 PPI inhibitors as inducers of mitophagy and their potent

172 Structurally distinct Keap1-Nrf2 PPI inhibitors promote mitochondrial turnover, while cov

173 Together, these findings reveal that nuclear PPI metabolism mediates an early damage response through

174 Here, we investigate roles of nuclear PPIs in DNA damage response by sequestering specific PPI

175 s with limited to no experimentally observed PPI, including Bacillus subtilis and Salmonella enterica

176 Of PPI users reporting fractures, the mean age was 65.3 yea

177 requently asked about the appropriateness of PPI therapy for specific patients.

178 The benefits of PPI therapy for appropriate indications need to be consi

179 There were 69 cases of PPI-related DHR, including SJS/TEN (n=27) and DRESS (n=1

180 many of the proposed adverse consequences of PPI therapy and apply established criteria for the deter

181 s into a signalling network for discovery of PPI targets and network-implicated tumour vulnerabilitie

182 We observed a relationship between dose of PPI taken and HE risk.

183 ved a modest association between duration of PPI use and scores for psychomotor speed and attention (

184 th FACS, SPARK enabled 51 fold enrichment of PPI-positive over PPI-negative cells.

185 increasing number of successful examples of PPI modulators, resulting in growing interest in this fi

186 rrence of HE, 38% (n = 445) had a history of PPI use before HE occurrence.

187 Initiation of PPI therapy and cumulative PPI exposure is associate wit

188 Thirteen patients allergic to one kind of PPI could tolerate other structurally different PPI with

189 iew of the known long-term safety profile of PPI, they can be a valuable addition to standard therapy

190 We conducted a study of a large series of PPI-related DHR, followed up their tolerability to alter

191 the Ns1tbe oligomers also resemble those of PPI peptide helices.

192 therapy (improving compliance and timing of PPI doses), or increasing PPI dosage to twice daily in s

193 All categories of PPIs, except rabeprazole, were associated with an increa

194 ep towards the molecular characterisation of PPIs implies the charting of their interfaces, that is,

195 ate at damage sites with local enrichment of PPIs.

196 ol to investigate the exquisite mechanism of PPIs.

197 (3.0%) received a prior >/=2-year supply of PPIs and 1063 (1.4%) received H2RAs (without PPI use).

198 (0.9%) received a prior >/=2-year supply of PPIs and 2247 (0.6%) H2RAs.

199 The adjusted OR for current use of PPIs and development of listeriosis was 2.81 (95% confid

200 Data on use of PPIs and other drugs and hospitalization diagnoses over

201 We calculated the association between use of PPIs and related drugs within 30 days (current use) and

202 ibitors (PPIs), focusing on long-term use of PPIs for three common indications: gastroesophageal refl

203 nsurance beneficiaries, we found that use of PPIs in patients with cirrhosis increases the risk for H

204 In the meantime, cautious use of PPIs is advised.

205 We hypothesized that long-term use of PPIs is associated with greater microbial translocation

206 In HIV, long-term use of PPIs was associated with increased microbial translocati

207 We identified new users of PPIs (n = 105,305) and new users of H2 blockers (H2B; n

208 Users of PPIs, compared with users of H2Bs, had an increased risk

209 Both >/=2 years of PPIs (adjusted odds ratio, 2.49; 95% confidence interval

210 fundoplication, 60% of the patients are off PPIs, and 16% require reoperation for recurrent GERD and

211 percentage of proximal esophageal reflux off-PPI did not change significantly after one year, but the

212 the pro-attentional drug, d-amphetamine, on PPI and neurocognition in antipsychotic-medicated schizo

213 f a single dose of amphetamine (10 mg po) on PPI and MATRICS Consensus Cognitive Battery (MCCB) perfo

214 ess induced by gemcitabine exposure based on PPIs map.

215 teins, depending on available information on PPIs, as we demonstrate in several examples.

216 MII-pH measurements on-PPI and with healthy controls will be useful in the furt

217 Current technologies, which assay one PPI at a time, are too low throughput to make it practic

218 African American race or PPI use with LDV/SOF +/- RBV was not associated with low

219 mehow resistant to PPI-based intervention or PPIs are inherently unable to suppress acid GER.

220 ss-hypersensitivity or tolerability to other PPI after their hypersensitivity episodes.

221 bled 51 fold enrichment of PPI-positive over PPI-negative cells.

222 es', where signals were detected for overall PPIs as well as for each of 5 generic ingredients (insuf

223 n bind simultaneously to a flexible peptidic PPI recognition motif and to a well-structured adapter p

224 ), including those receiving long-term PPIs (PPI+ group) or not (PPI- group), were enrolled.

225 Prescribed PPIs were associated with increased risk of listeriosis.

226 ore than 5 million new users of prescription PPIs and H2RAs.

227 lans, we found no evidence that prescription PPIs increase risk of MI compared with prescription H2RA

228 re providers to carefully consider prolonged PPI use by patients with cirrhosis.

229 e use of small molecule poly(propylenimine) (PPI) in linear and dendritic architectures supported in

230 For the H.pylori PPIs dataset, our method achieves 87.59 % accuracy and 8

231 fting the light window, we could reconstruct PPI time-courses.

232 Patients who cannot reduce PPIs should consider ambulatory esophageal pH/impedance

233 Regular PPI use was not associated with increased risk of stroke

234 Complete collection of repeated PPI and H2B dispensations at pharmacies in Sweden allowe

235 A total of 25 reproducible PPIs were found for a selected set of 10 Giles proteins,

236 The estimated NNT for routine PPI use to prevent one disabling or fatal upper gastroin

237 trointestinal, the estimated NNT for routine PPI use to prevent such bleeds is low, and co-prescripti

238 upper gastrointestinal bleeding with routine PPI co-prescription on the basis of Kaplan-Meier risk es

239 drugs (mainly aspirin based, without routine PPI use) after the event in the Oxford Vascular Study fr

240 based antiplatelet treatment without routine PPI use, the long-term risk of major bleeding is higher

241 s and global network aligners on large scale PPI data and observe that three methods, HUBALIGN, L-GRA

242 with current methods, quantitatively scores PPIs with enough accuracy and sensitivity to detect chan

243 The cross-reactivity to structurally similar PPI was also observed in LAT assay.

244 eactions to alternative structurally similar PPI.

245 Best Practice Advice 10: Specific PPI formulations should not be selected based on potenti

246 DNA damage response by sequestering specific PPIs with the expression of nuclear-targeted PH domains,

247 PPI, in this study, we show that stabilizing PPI may also be therapeutically beneficial.

248 nces in MI risk between patients who started PPIs vs H2RAs for the first 12 months, either in the com

249 ent for established risk factors for stroke, PPI use was associated with a significant increase in ri

250 proposed a new representation for structural PPI networks inspecting the alternative conformations of

251 Tackling PPIs, particularly by stabilizing clinically favored con

252 to be significantly lower in patients taking PPI (P = .0052).

253 PPI strategies, such as selecting the target PPI site on the basis of its functionality, are discusse

254 Targeting PPIs with small molecules can be challenging owing to la

255 However, data are lacking on long-term PPI use and cognitive function.

256 Best Practice Advice 8: Long-term PPI users should not routinely raise their intake of cal

257 Best Practice Advice 9: Long-term PPI users should not routinely screen or monitor bone mi

258 Best Practice Advice 7: Long-term PPI users should not routinely use probiotics to prevent

259 rett's esophagus should consider a long-term PPI.

260 and symptomatic GERD should take a long-term PPI.

261 y (ART), including those receiving long-term PPIs (PPI+ group) or not (PPI- group), were enrolled.

262 est Practice Advice 6: The dose of long-term PPIs should be periodically reevaluated so that the lowe

263 uncomplicated GERD who respond to short-term PPIs should subsequently attempt to stop or reduce them.

264 ollment, PPI+ group lost more CD4 cells than PPI- (-18 vs. 54 cells/mm3, P = .03).

265 o have hypertension and receive statins than PPI-.

266 haviour of network aligners and observe that PPI networks are almost entirely aligned with a handful

267 These results suggest that PPI-based CO2 sorbents may allow for longer sorbent work

268 Our data do not support the suggestion that PPI use increases dementia risk.

269 Here Llorente et al. show that PPIs induce bacterial overgrowth of enterococci, which,

270 The PPI phosphatidylinositol (3,5)-bisphosphate (PI(3,5)P2)

271 ne loading or aminopolymer architecture, the PPI-based sorbents are found to be more efficient for CO

272 rporate the topological information from the PPI network to evaluate the potential of a given set of

273 nknown meiotic proteins, and we show how the PPI network can be used to prioritise candidates for ana

274 We find that 21% of the proteins in the PPI network are indispensable.

275 cial to obtain the tertiary structure of the PPIs.

276 Consistent with both their PPI and learning defects, cortical pyramidal neurons fro

277 Mapping protein structures to these PPI networks not only provides structural details of eac

278 vector yeast two-hybrid screening, and these PPIs were further supported by the results of coimmunopr

279 or the discovery of novel inhibitors of this PPI.

280 ion of p38 and its activation of MYC through PPI.

281 mozygous patients were randomly allocated to PPI (pantoprazole 40 mg/day) or placebo for 12 months.

282 s, and investigated the T-cell reactivity to PPI in PPI-related DHR patients.

283 Because our primary hypothesis related to PPI use, our findings for H2RAs should be interpreted wi

284 r patients with IPF are somehow resistant to PPI-based intervention or PPIs are inherently unable to

285 d association between cumulative exposure to PPIs and risk of CKD progression.

286 Among individuals who did not use PPIs regularly, duration of H2RA use was associated with

287 Forty-three and 49% of the patients used PPIs (NS).

288 affinity pulldown, a gold-standard in vitro PPI interrogation technique, to perform nanoscale pulldo

289 nd specific to quantify both strong and weak PPIs between influenza virus polymerase subunits.

290 In patients when PPI is necessary for treatment, switching to structurall

291 We investigated whether PPI predisposes patients with cirrhosis to HE using a la

292 RBV did not affect SVR (89.7% [131/146] with PPI and 91.5% [613/670] without PPI).

293 elated to chronic conditions associated with PPI use.

294 than 365 cDDDs, respectively, compared with PPI nonusers.

295 We retrospectively analyzed patients with PPI-related DHR from multiple medical centers in Taiwan

296 We evaluated MI risk associated with PPIs compared with histamine-2 receptor antagonists (H2R

297 previously reported as being associated with PPIs, such as 'rib fractures', where signals were detect

298 lysis, sCD14 levels remained associated with PPIs.

299 31/146] with PPI and 91.5% [613/670] without PPI).

300 PPIs and 1063 (1.4%) received H2RAs (without PPI use).